Search Results

The Accu-Stat™ Drugs of Abuse Home Test Cup for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Ecstasy (MDMA), Opiates (OPI), and Phencyclidine (PCP), is a screening test for the rapid detection of three to seven of the above listed drugs in a variety of combinations human urine. The designated cut-off concentrations for these drugs are as follows: Marijuana at 50 ng/ml, Cocaine at 300 ng/ml, Amphetamine at 1000 ng/ml, Methamphetamine at 1000 ng/ml, Ecstasy at 500 ng/ml, Opiates at 2000 ng/ml, and Phencyclidine at 25 ng/ml. The tests are intended for over-the-counter (OTC) consumer use as the first step in a two-step process to provide consumers with information concerning the presence of the above stated drugs or their metabolites in a urine sample. Information, along with the materials for shipping a portion of the urine specimen to the laboratory for confirmation testing of a preliminary positive result, the second step in the process, is provided.

The Accu-Stat™ Drugs of Abuse Home Test Cup for Marijuana, Cocaine, Amphetamine, Methamphetamine, Ecstasy, Opiates, and Phencyclidine, like other commercially available drug screening tests, qualitatively measures the presence or absence of THC, COC, AMP, mAMP, MDMA, OPI, PCP and their metabolites in urine, using a one step, rapid chromatographic immunoassay which operates under the principle of competitive binding. Drugs. which may be present in the urine specimen, compete against the drug conjugate for binding sites on the antibody. During testing, a urine specimen migrates upward by capillary action. Marijuana, if present in the urine specimen below 50 ng/ml, and the other drugs being tested for, if below the cut-off levels stated in Attachment 3 Table 2, will not saturate the binding sites of the antibody coated particles in the test device. The antibody coated particles will then be captured by immobilized marijuana, cocaine, or other listed drug conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the marijuana level is above the 50 ng/ml because it will saturate all the binding sites of antimarijuana antibodies. The same holds true for cocaine and the other drugs if the level is above the cut-off. It will saturate all the binding sites of anticocaine (or other drug) antibodies and therefore the colored line will not form in the test region. A drug-positive urine specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative urine specimen will generate a line in the test region because of the absence of a drug competition. To serve as a procedural control, a colored line will always appear at the control line region if the test has been performed properly.

The Accu-Stat™ Drugs of Abuse Home Test Cup is a rapid screening test for the detection of various drugs in human urine. The device is intended for over-the-counter (OTC) consumer use as the first step in a two-step process, with confirmatory laboratory testing for preliminary positive results.

1. Acceptance Criteria and Reported Device Performance:

The document describes the cut-off concentrations for each drug as acceptance criteria for qualitative detection. The device is designed to indicate the presence of a drug if its concentration in urine is above the specified cut-off. While the document implies the device meets these criteria through a "consumer study," it does not provide detailed performance metrics (e.g., sensitivity, specificity, accuracy) against these cut-off levels in the format of a table. Instead, it makes a general statement about "excellent overall performance."

2. Sample Size Used for the Test Set and Data Provenance:

The document mentions "consumer studies" but does not specify the sample size used for the test set. The provenance of the data (e.g., country of origin, retrospective or prospective) is not explicitly stated. However, given its application for OTC consumer use, it implies real-world use conditions.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts:

The document does not specify the number or qualifications of experts used to establish the ground truth for the test set in the context of the "consumer studies." The ground truth for this type of device, as implied, would likely be established through confirmed laboratory results for comparison, but the details are not provided.

4. Adjudication Method for the Test Set:

No adjudication method is described for the test set.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

An MRMC study was not described, nor is there any mention of AI assistance. This device is a rapid immunoassay test cup, not an AI-powered diagnostic system.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done:

The device is a standalone immunoassay test cup that provides a visual result. Its performance is inherent in the chemical reactions and visual line formation, which is essentially "algorithm only" in the sense of the chemical mechanism. The consumer interprets the visual result, which constitutes the human-in-the-loop for interpretation, but the core detection is standalone. The document states that the "consumer can use the Accu-Stat™ Home Drug Tests to obtain immediate, preliminary information," indicating standalone performance in generating the result.

7. The Type of Ground Truth Used (expert consensus, pathology, outcomes data, etc.):

The ground truth used for evaluating the device would be the confirmed laboratory results of urine specimens. The "two-step process" explicitly states that preliminary positive results require "confirmatory testing of preliminary positive results," indicating that laboratory confirmation serves as the ultimate ground truth.

8. The Sample Size for the Training Set:

The document does not detail a separate "training set" as would be applicable to machine learning algorithms. For an immunoassay, the "training" (development and optimization) would refer to the extensive laboratory work to ensure the antibodies and reagents perform as expected across a range of concentrations and interferents. This information is not provided.

9. How the Ground Truth for the Training Set Was Established:

This information is not provided, as the concept of a training set ground truth, in the context of an immunoassay, differs from its application in machine learning. Development of the immunoassay involves establishing its analytical sensitivity and specificity against known concentrations of drugs and metabolites, with ground truth established by precisely formulated drug solutions and confirmed analytical methods.

Ask a specific question about this device